Lunai Bioworks PE Ratio 2013-2025 | LNAI
Current and historical p/e ratio for Lunai Bioworks (LNAI) from 2013 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Lunai Bioworks PE ratio as of November 14, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Lunai Bioworks PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-11-14 | 1.06 | 0.00 | |
| 2025-06-30 | 2.89 | $-3.20 | 0.00 |
| 2025-03-31 | 5.43 | $-7.70 | 0.00 |
| 2024-12-31 | 8.36 | $-9.30 | 0.00 |
| 2024-09-30 | 4.83 | $-9.60 | 0.00 |
| 2024-06-30 | 17.50 | $-8.20 | 0.00 |
| 2024-03-31 | 26.50 | $-7.80 | 0.00 |
| 2023-12-31 | 31.70 | $-7.00 | 0.00 |
| 2023-09-30 | 44.70 | $-6.30 | 0.00 |
| 2023-06-30 | 5.67 | $-4.90 | 0.00 |
| 2023-03-31 | 9.15 | $-0.80 | 0.00 |
| 2022-12-31 | 10.30 | $-1.20 | 0.00 |
| 2022-09-30 | 18.10 | $-2.50 | 0.00 |
| 2022-06-30 | 19.30 | $-4.50 | 0.00 |
| 2022-03-31 | 82.50 | $-8.20 | 0.00 |
| 2021-12-31 | 72.90 | $-7.90 | 0.00 |
| 2021-09-30 | 67.30 | $-7.20 | 0.00 |
| 2021-06-30 | 49.70 | $-5.20 | 0.00 |
| 2021-03-31 | 35.40 | $-1.50 | 0.00 |
| 2020-12-31 | 29.50 | $-0.90 | 0.00 |
| 2020-09-30 | 35.80 | $-0.30 | 0.00 |
| 2020-06-30 | 42.10 | $-1.20 | 0.00 |
| 2020-03-31 | 30.00 | $0.70 | 42.86 |
| 2019-12-31 | 50.20 | $-0.30 | 0.00 |
| 2019-09-30 | 55.00 | $-5.30 | 0.00 |
| 2019-06-30 | 45.00 | $-5.00 | 0.00 |
| 2019-03-31 | 69.40 | $-8.60 | 0.00 |
| 2018-12-31 | 70.00 | $-8.50 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.025B | $0.000B |
| Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company. Lunai Bioworks Inc., formerly known as RENOVARO INC, is based in LOS ANGELES. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $48.084B | 58.67 |
| Tempus AI (TEM) | United States | $12.183B | 0.00 |
| Doximity (DOCS) | United States | $9.342B | 38.47 |
| Hims & Hers Health (HIMS) | United States | $8.418B | 68.48 |
| IRhythm Technologies (IRTC) | United States | $5.504B | 0.00 |
| Hinge Health (HNGE) | United States | $3.224B | 0.00 |
| Privia Health (PRVA) | United States | $2.884B | 180.38 |
| Inspire Medical Systems (INSP) | United States | $2.509B | 41.51 |
| Heartflow (HTFL) | United States | $2.383B | 0.00 |
| 10x Genomics (TXG) | United States | $2.011B | 0.00 |
| Enovis (ENOV) | United States | $1.715B | 9.01 |
| Omnicell (OMCL) | United States | $1.576B | 32.22 |
| Azenta (AZTA) | United States | $1.364B | 59.50 |
| Phreesia (PHR) | United States | $1.304B | 0.00 |
| Schrodinger (SDGR) | United States | $1.299B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.276B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.900B | 0.00 |
| Claritev (CTEV) | United States | $0.715B | 0.00 |
| Talkspace (TALK) | United States | $0.538B | 108.33 |
| Butterfly Network (BFLY) | United States | $0.536B | 0.00 |
| Veradigm (MDRX) | United States | $0.523B | 0.00 |
| Standard BioTools (LAB) | United States | $0.477B | 0.00 |
| Evolent Health (EVH) | United States | $0.466B | 0.00 |
| Carlsmed (CARL) | United States | $0.349B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.348B | 0.00 |
| TruBridge (TBRG) | United States | $0.306B | 14.05 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.291B | 0.00 |
| CapsoVision (CV) | United States | $0.239B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.212B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.200B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.172B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.170B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.160B | 0.00 |
| CareCloud (CCLD) | United States | $0.133B | 7.28 |
| EUDA Health Holdings (EUDA) | Singapore | $0.110B | 0.00 |
| Outset Medical (OM) | United States | $0.085B | 0.00 |
| NetraMark Holdings (AINMF) | Canada | $0.067B | 0.00 |
| American Well (AMWL) | United States | $0.066B | 0.00 |
| Pulmonx (LUNG) | United States | $0.061B | 0.00 |
| HeartBeam (BEAT) | United States | $0.054B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.049B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.045B | 0.00 |
| 111 (YI) | China | $0.035B | 0.00 |
| Precipio (PRPO) | United States | $0.031B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.027B | 0.00 |
| Zhongchao (ZCMD) | China | $0.017B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.015B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.010B | 0.00 |
| Movano (MOVE) | United States | $0.009B | 0.00 |
| HeartSciences (HSCS) | United States | $0.008B | 0.00 |
| PROFUSA (PFSA) | United States | $0.008B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.007B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.002B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.001B | 0.00 |